KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the…
The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.The clinical site is…
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery PlatformBETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Gain…
The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestonesJERUSALEM,…
Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…
Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea’s experimental drug,…
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will…
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 –…
TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that two…
JEDDAH, Saudi Arabia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) in Jeddah successfully…